Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

The Impact of Solute Carrier (SLC) Drug Uptake Transporter Loss in Human and Rat Cryopreserved Hepatocytes on Clearance Predictions

Patrik Lundquist, Johan Lööf, Anna-Karin Sohlenius-Sternbeck, Eva Floby, Jenny Johansson, Johan Bylund, Janet Hoogstraate, Lovisa Afzelius and Tommy B. Andersson
Drug Metabolism and Disposition March 2014, 42 (3) 469-480; DOI: https://doi.org/10.1124/dmd.113.054676
Patrik Lundquist
CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje, (P.L., J.L., A.-K.S.-S., E.F., J.J., J.B., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal, (P.L., T.B.A.); Department of Pharmacy, Uppsala University, Uppsala, (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, (T.B.A.), Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johan Lööf
CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje, (P.L., J.L., A.-K.S.-S., E.F., J.J., J.B., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal, (P.L., T.B.A.); Department of Pharmacy, Uppsala University, Uppsala, (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, (T.B.A.), Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna-Karin Sohlenius-Sternbeck
CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje, (P.L., J.L., A.-K.S.-S., E.F., J.J., J.B., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal, (P.L., T.B.A.); Department of Pharmacy, Uppsala University, Uppsala, (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, (T.B.A.), Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva Floby
CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje, (P.L., J.L., A.-K.S.-S., E.F., J.J., J.B., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal, (P.L., T.B.A.); Department of Pharmacy, Uppsala University, Uppsala, (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, (T.B.A.), Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jenny Johansson
CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje, (P.L., J.L., A.-K.S.-S., E.F., J.J., J.B., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal, (P.L., T.B.A.); Department of Pharmacy, Uppsala University, Uppsala, (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, (T.B.A.), Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johan Bylund
CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje, (P.L., J.L., A.-K.S.-S., E.F., J.J., J.B., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal, (P.L., T.B.A.); Department of Pharmacy, Uppsala University, Uppsala, (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, (T.B.A.), Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janet Hoogstraate
CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje, (P.L., J.L., A.-K.S.-S., E.F., J.J., J.B., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal, (P.L., T.B.A.); Department of Pharmacy, Uppsala University, Uppsala, (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, (T.B.A.), Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lovisa Afzelius
CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje, (P.L., J.L., A.-K.S.-S., E.F., J.J., J.B., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal, (P.L., T.B.A.); Department of Pharmacy, Uppsala University, Uppsala, (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, (T.B.A.), Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tommy B. Andersson
CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje, (P.L., J.L., A.-K.S.-S., E.F., J.J., J.B., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal, (P.L., T.B.A.); Department of Pharmacy, Uppsala University, Uppsala, (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, (T.B.A.), Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Information

vol. 42 no. 3 469-480
DOI 
https://doi.org/10.1124/dmd.113.054676
PubMed 
24396146

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received October 2, 2013
  • Accepted January 6, 2014
  • Published online February 12, 2014.

Article Versions

  • Earlier version (January 6, 2014 - 11:49).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Patrik Lundquist,
  2. Johan Lööf,
  3. Anna-Karin Sohlenius-Sternbeck,
  4. Eva Floby,
  5. Jenny Johansson,
  6. Johan Bylund,
  7. Janet Hoogstraate,
  8. Lovisa Afzelius, and
  9. Tommy B. Andersson
  1. CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje, (P.L., J.L., A.-K.S.-S., E.F., J.J., J.B., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal, (P.L., T.B.A.); Department of Pharmacy, Uppsala University, Uppsala, (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, (T.B.A.), Sweden
  1. Address correspondence to:
    Tommy B. Andersson, Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Pepparedsleden 1, SE-431 83 Mölndal, Sweden. E-mail: Tommy.B.Andersson{at}astrazeneca.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: August 2017 to September 2023

AbstractFullPdf
Aug 201722611
Sep 201743617
Oct 201724726
Nov 201744424
Dec 2017955916
Jan 2018349812
Feb 2018631221
Mar 2018823919
Apr 2018213320
May 2018011511
Jun 201807013
Jul 201814013
Aug 201814819
Sep 201854321
Oct 201846913
Nov 2018610222
Dec 201818219
Jan 201979316
Feb 2019523110
Mar 201968211
Apr 201930812
May 20193833
Jun 20191806
Jul 20192646
Aug 20193335
Oct 20193448
Nov 20193424
Dec 201921174
Jan 202010136
Feb 2020501211
Mar 20205056
May 20202152
Jun 2020832
Jul 20201702
Aug 2020734
Sep 202024126
Oct 202023124
Nov 20201966
Dec 20202575
Jan 202120154
Feb 202125148
Mar 20213094
Apr 20215256
May 20217565
Jun 20211363
Jul 20212286
Aug 20211586
Sep 20214275
Oct 20211385
Nov 20213129
Dec 20212832
Jan 20221463
Feb 20221042
Mar 20222754
Apr 20221363
May 20221523
Jun 20221930
Jul 202244120
Aug 20223278
Sep 20222461
Oct 202226153
Nov 202224611
Dec 20221624
Jan 20233673
Feb 20231229
Mar 20233453
Apr 20231036
May 202332134
Jun 20231232
Jul 202341618
Aug 202343910
Sep 2023743

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 42 (3)
Drug Metabolism and Disposition
Vol. 42, Issue 3
1 Mar 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Impact of Solute Carrier (SLC) Drug Uptake Transporter Loss in Human and Rat Cryopreserved Hepatocytes on Clearance Predictions
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Drug Uptake Transporters in Cryopreserved Hepatocytes

Patrik Lundquist, Johan Lööf, Anna-Karin Sohlenius-Sternbeck, Eva Floby, Jenny Johansson, Johan Bylund, Janet Hoogstraate, Lovisa Afzelius and Tommy B. Andersson
Drug Metabolism and Disposition March 1, 2014, 42 (3) 469-480; DOI: https://doi.org/10.1124/dmd.113.054676

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Drug Uptake Transporters in Cryopreserved Hepatocytes

Patrik Lundquist, Johan Lööf, Anna-Karin Sohlenius-Sternbeck, Eva Floby, Jenny Johansson, Johan Bylund, Janet Hoogstraate, Lovisa Afzelius and Tommy B. Andersson
Drug Metabolism and Disposition March 1, 2014, 42 (3) 469-480; DOI: https://doi.org/10.1124/dmd.113.054676
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Ontogeny of CPPGL
  • Expression of AKR and SDR Isoforms in the Human Intestine
  • Metabolism of Lufotrelvir in Humans
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics